coin-img-ETHETH+0.60%coin-img-BTCBTC+0.38%coin-img-SOLSOL-1.15%coin-img-XRPXRP+0.16%coin-img-USDCUSDC+0.02%coin-img-HYPEHYPE+3.41%coin-img-NEARNEAR+9.66%coin-img-SUISUI+1.99%coin-img-ETHETH+0.60%coin-img-BTCBTC+0.38%coin-img-SOLSOL-1.15%coin-img-XRPXRP+0.16%coin-img-USDCUSDC+0.02%coin-img-HYPEHYPE+3.41%coin-img-NEARNEAR+9.66%coin-img-SUISUI+1.99%coin-img-ETHETH+0.60%coin-img-BTCBTC+0.38%coin-img-SOLSOL-1.15%coin-img-XRPXRP+0.16%coin-img-USDCUSDC+0.02%coin-img-HYPEHYPE+3.41%coin-img-NEARNEAR+9.66%coin-img-SUISUI+1.99%coin-img-ETHETH+0.60%coin-img-BTCBTC+0.38%coin-img-SOLSOL-1.15%coin-img-XRPXRP+0.16%coin-img-USDCUSDC+0.02%coin-img-HYPEHYPE+3.41%coin-img-NEARNEAR+9.66%coin-img-SUISUI+1.99%
user-avatar
ABC News & Headlines – Australian Broadcasting Corporation

Doctors and pharmacists criticise Eli Lilly plan to deliver Mounjaro directly to patients

AI Market Summary
Eli Lilly's launch of LillyDirect to distribute Mounjaro via online fulfillment has drawn pushback from doctors and pharmacists citing weaker oversight, reduced face-to-face interaction, and safety risks, especially alongside telehealth prescribing. While the company argues the model remains within Australian regulatory requirements and may modestly improve affordability, the public criticism elevates reputational and regulatory scrutiny risk around GLP-1 commercialization and distribution practices.
Impact level
● Low
Affected assets
NCSKLLY2USD/USDT-1.99%
AI Insight · NCSKLLY2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Eli Lilly has launched an online platform, LillyDirect, that bypasses traditional pharmacies to deliver the GLP-1 drug Mounjaro to patients’ homes. The service initially offers tirzepatide injections for type 2 diabetes and obesity, with private purchases costing up to $700 a month. Some users say buying through the platform can be about $50 cheaper. Doctors and pharmacists have criticised the model, warning it could put patient safety at risk.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.